Brokerages Set Pyxis Oncology, Inc. (NASDAQ:PYXS) PT at $9.20

Pyxis Oncology, Inc. (NASDAQ:PYXS) has earned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $9.20.

A number of equities analysts recently commented on the company. Royal Bank of Canada restated an “outperform” rating and set a $8.00 target price on shares of Pyxis Oncology in a report on Wednesday, March 19th. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Pyxis Oncology in a research report on Wednesday, March 19th.

Institutional Investors Weigh In On Pyxis Oncology

Several large investors have recently bought and sold shares of the stock. Intech Investment Management LLC acquired a new position in shares of Pyxis Oncology during the third quarter worth about $55,000. MetLife Investment Management LLC lifted its stake in Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after acquiring an additional 5,484 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Pyxis Oncology during the 3rd quarter worth approximately $1,405,000. State Street Corp increased its position in shares of Pyxis Oncology by 28.0% in the 3rd quarter. State Street Corp now owns 951,251 shares of the company’s stock valued at $3,491,000 after purchasing an additional 208,344 shares during the last quarter. Finally, Jane Street Group LLC increased its position in shares of Pyxis Oncology by 40.8% in the 3rd quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock valued at $182,000 after purchasing an additional 14,349 shares during the last quarter. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Stock Performance

Pyxis Oncology stock opened at $1.15 on Friday. The company’s 50 day simple moving average is $1.31 and its 200-day simple moving average is $2.31. Pyxis Oncology has a 1 year low of $0.99 and a 1 year high of $6.18. The company has a market capitalization of $70.83 million, a price-to-earnings ratio of -1.12 and a beta of 1.11.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.01. The firm had revenue of $16.15 million during the quarter. Equities analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.